Evidence map›Paper›PMID 37819777›Full record

ArticlePigment cell & melanoma research2023

Progress in melanoma treatment: Patient's perspectives.

Gretchen M Alicea, Jessie Villanueva, Marie R Webster, Vito W Rebecca

Abstract read
In one paragraph

Article in Pigment cell & melanoma research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gretchen M AliceaJohns Hopkins Whiting School of Engineering, Baltimore, Maryland, USA.
Jessie VillanuevaThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Marie R WebsterLankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA.ORCID 0000-0001-7633-7150
Vito W RebeccaJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Funding

Targeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI GIMOTTY, PHYLLIS A. · 2021 to 2025
$11.3M
Histone modifications regulating phenotype plasticity: Role of non-canonical Wnt signalingR00CA208012 · NCI · LANKENAU INSTITUTE FOR MEDICAL RESEARCH · PI WEBSTER, MARIE RUTH · 2019 to 2021
$744k
Dissecting clonal diversity in melanoma to overcome therapy resistance andmetastasisK01CA245124 · NCI · JOHNS HOPKINS UNIVERSITY · PI REBECCA, VITO WILLIAM · 2020 to 2024
$595k
NCI NIH HHS K01 CA245124NCI NIH HHS P50 CA261608NCI NIH HHS R00 CA208012
6 · The paper itself

Abstract

Upon the 20th Anniversary of the Society for Melanoma Research, we highlight the perspectives of patients aiming to help improve future experiences, outcomes, and their quality of life over the next 20 years. Five melanoma patients generously shared their inspiring and enlightening stories of diagnosis, treatment, and outcomes. Many patients had excellent medical teams that synergistically worked together to provide an accurate diagnosis, effective treatment options, and supportive care. However, it is clear that health inequities persist in communities where people of color are predominant, affecting early detection, patient experience, and outcomes. These stories shed light on the unique challenges faced by patients and how the lack of melanoma awareness and adequate resources, especially in communities of color or low socioeconomic status, can contribute to disparate outcomes in melanoma care. We expect that these stories will raise awareness about the progress in melanoma treatment but also the existent disparities in melanoma diagnosis and treatment and the importance of early detection and prevention.

Indexed as

MelanomaQuality of LifeHumansdiagnosismelanoma patientstherapy

Identifiers

PMID37819777
PMCPMC10896641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.